Premium
Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness
Author(s) -
Tan O.,
Shrestha R.,
Cunich M.,
Schofield D.J.
Publication year - 2018
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.13199
Subject(s) - cost effectiveness , medicine , medline , dna sequencing , cancer , bioinformatics , intensive care medicine , oncology , risk analysis (engineering) , biology , genetics , gene , biochemistry
Uptake of next‐generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost‐effectiveness of applying NGS to cancer care. A systematic search for full‐length original research articles on the clinical effectiveness and cost‐effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost‐effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost‐effectiveness ratio and sensitivity analysis outcomes are reported for the cost‐effectiveness articles. Fifty‐six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost‐effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost‐effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost‐effectively.